FDA reconsidering Capricor’s snubbed DMD cell therapy after 'lifting' rejection
Fuente:
FierceBiotech
The FDA has resumed review of Capricor Therapeutics’ previously rejected Duchenne muscular dystrophy cell therapy following the biotech’s submission of more clinical data.